-  99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models -  ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope. Initial pre

- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology - Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditioning - Actinium's targeted radiotherapy programs expanded to four multi-billion-dollar market opportunities NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:A

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure - Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market - Presentation follows Investor KOL Event and Company Update on March 25th NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a bus

B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00

HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60

4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

-       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of

-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development

-  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

-  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm -  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients -  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 -  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover -  Iomab-B was

-  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,

SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)